dsm-firmenich announces share repurchase program to cover share plans and reduce capital Press Release dsm-firmenich announces share repurchase program to cover share plans and reduce capital Kaiseraugst (Switzerland), Maastricht (Netherlands), April 1, 2025 dsm-firmenich, innovators in nutrition, health, and beauty announced on February 13, 2025 its intention to repurchase ordinary shares with an aggregate market value of €1 billion and reduce its issued capital. This share repurchase program will start for an initial €500 million and will be increased to €1 billion upon the completion ...
dsm-firmenich showcases integrated approach to sustainability and business performance at Sustainability Investor Day Press Release dsm-firmenich showcases integrated approach to sustainability and business performance at Sustainability Investor Day Kaiseraugst (Switzerland), Maastricht (Netherlands), March 25, 2025 dsm-firmenich, innovators in nutrition, health, and beauty, will today hold its Sustainability Investor Day in Kaiseraugst. At the event, the company will present its strategic approach to sustainability to investors, analysts and other stakeholders. Senior company represe...
dsm-firmenich publishes 2024 Integrated Annual Report Press Release dsm-firmenich publishes 2024 Integrated Annual Report Kaiseraugst (Switzerland), Maastricht (Netherlands), February 28, 2025 dsm-firmenich today announces the publication of its 2024 Integrated Annual Report (IAR). The 2024 IAR contains detailed insights into dsm-firmenich’s financial and non-financial progress during its first full year as an integrated company. Through its highly innovative portfolio of nutritional, natural and renewable ingredients, together with complementary science capabilities and technologies, d...
Dsm firmenich has retrieved a solid earnings momentum in FY24, even without including the temporary benefit from higher vitamin prices on the back of a supply side disruption. Whilst the FY25 adjusted EBITDA growth guidance of at least 13% is still boosted by a combination of savings and synergies, we believe a mid single digit growth for the medium term is a realistic scenario. We still appreciate dsm-firmenich for its broad portfolio and market leading positions. The upcoming separation of the...
dsm-firmenich issues €750 million long-term bond Press Release dsm-firmenich issues €750 million long-term bond Kaiseraugst (Switzerland), Maastricht (Netherlands), February 19, 2025 dsm-firmenich today announces the successful launch of a €750 million bond with an 11-year maturity due in 2036, at a coupon of 3.375%. The bond will be issued by DSM B.V. and will be guaranteed by DSM-Firmenich AG pursuant to the previously established . The proceeds of the new bond will be used for general corporate purposes, including the refinancing of existing indebtedness. ...
Below are the highlights from the 4Q24 results conference call. 4Q adj EBITDA jumped by 37% and was about 2% better than our and consensus forecasts. Dsm-firmenich guides for at least 13% adj. EBITDA growth in FY25, on the back of a combination of synergies, savings and continued benefit from temporary high vitamin prices. The company is still looking to exit the ANH business and, reflecting the strong balance sheet, has announced a € 1bn share buyback program. We still appreciate dsm-firmenich ...
Ackermans & van Haaren: Acquisition of boutique wealth manager Petram & Co. Alfen: Takes care of costs and debt, guidance misses. Arcadis: Solid backlog growth provides comfort. BAM: A friend of ours, 10% yield. CM.com: 2H24 results – FCF positive, capital restructuring. dsm-firmenich: Cash in, cash back. Flow Traders: Roller Coaster. KBC: Encouraging outlook to 2027, poor dividend. RELX: FY24 results – in line, £1.5bn buyback in 2025. Talabat: A beat at its maiden 4Q24 results...
4Q adj EBITDA jumped by 37% and was about 2% better than our and consensus forecasts. Dsm-firmenich guides for at least 13% adj. EBITDA growth in FY25, on the back of a combination of synergies, savings and continued benefit from temporary high vitamin prices. The company is still looking to exit the ANH business and, reflecting the strong balance sheet, has announced a € 1bn share buyback program. We still appreciate dsm-firmenich for its broad portfolio and market leading positions. The upcomi...
Unfortunately, this report is not available for the investor type or country you selected.
Report is subscription only.
Thank you, your report is ready.
Thank you, your report is ready.